anoth cf domin continu
valuat peak downgrad share hold
vertex report cystic fibrosi cf revenu repres
sequenti growth beat consensu result includ
kalydeco revenu vs consensu orkambi vs
consensu symdeko vs consensu total cf
revenu y/i non-gaap opex
vertex end year cash non-gaap ep beat
consensu
guidanc total cf revenu non-gaap opex
anoth great quarter year vertex cf franchis like
continu grow symdeko symkevi launch ramp us eu
tripl combin move closer approv turn share
continu rise approach price target question
much higher valuat go well vertex
domin cf continu lower rate hold buy
valuat pt remov prior
commerci updat symdeko launch seen swift uptak demand
elig group age symkevi launch underway eu revenu
label expans year-old patient expect orkambi
kalydeco saw label expans patient young month old
kalydeco bring total address market kalydeco orkambi
symdeko patient current vertex product kalydeco hit
mark first time also reimburs agreement
establish australia sweden denmark contribut
overal higher revenu
tripl combo plu tezacaftor ivacaftor
vertex report posit data see note link
phase trial homozygot improv vs
placebo function heterozygot improv
vs placebo trial tripl combo
expect report data win tripl expect
submit nda note approv therapi
approv would bring total address popul
pain inhibitor posit data multipl pain indic
acut pain bunionectomi surgeri chronic pain caus osteoarthr
small fiber nephropathi dose rang studi bunionectomi pain on-going
support potenti pivot develop data addit pain asset
enter clinic
disord clinic develop initi decemb patient across
us eu addit asset pre-clin develop
sickl cell diseas scd thalassemia crispr gene
edit collabor crispr crsp nr track
scd trial underway indic
model chang model updat reflect guidanc non-gaap ep
estim increas
also remov pt lower rate hold buy valuat
thousand except per share data
interest incom net
loss discontinu oper
net incom attribut vertex
compani report maxim group estim
